State Street’s Artelo Biosciences ARTL Stock Holding History

State Street’s Portfolio ARTL Stock Details ARTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5	Closed	-$4K	–	4933
2022 Q2	$4K	Hold	5	–	–	﹤0.01%	4939
2022 Q1	$6K	Buy	5 +1	+25%	+$1.03K	﹤0.01%	4912
2021 Q4	$5K	Buy	+4	New	+$7.11K	﹤0.01%	4793

Other funds holding ARTL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

State Street's ARTL Position: Q3 2022 in Review

State Street sold out of Artelo Biosciences (ARTL) in Q3 2022, closing a stake of 5 shares — an estimated $4K sold.

State Street first reported a position in ARTL in Q4 2021 and held it in 3 quarters. The position peaked at $6K in Q1 2022. 6 funds tracked by Wall St. Rank hold ARTL as of Q3 2022.

State Street reported no remaining Artelo Biosciences position as of Q3 2022 after selling out during the quarter.
State Street sold 5 Artelo Biosciences shares in Q3 2022, an estimated $4K.
State Street first reported a position in Artelo Biosciences in Q4 2021 and held it in 3 quarters.
State Street's Artelo Biosciences position peaked at $6K in Q1 2022.
6 funds tracked by Wall St. Rank held Artelo Biosciences as of Q3 2022.

Based on State Street's 13F filing for Q3 2022, filed 15 Nov 2022.